|
|
Volumn 376, Issue 1, 2017, Pages 4-7
|
|
Oligonucleotide therapeutics - A new class of cholesterol-lowering drugs
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ASIALOGLYCOPROTEIN RECEPTOR;
INCLISIRAN;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
N ACETYLGALACTOSAMINE;
OLIGONUCLEOTIDE;
REVUSIRAN;
RNA INDUCED SILENCING COMPLEX;
SMALL INTERFERING RNA;
ALN-PCS;
HYPOCHOLESTEROLEMIC AGENT;
CHOLESTEROL BLOOD LEVEL;
DRUG ACTIVITY;
DRUG COST;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG POTENCY;
DRUG SAFETY;
GENE SILENCING;
HUMAN;
PRIORITY JOURNAL;
REVIEW;
RNA INTERFERENCE;
CHEMISTRY;
DRUG DEVELOPMENT;
LIVER CELL;
METABOLISM;
RNAI THERAPEUTICS;
ACETYLGALACTOSAMINE;
ANTICHOLESTEREMIC AGENTS;
DRUG DISCOVERY;
HEPATOCYTES;
HUMANS;
RNA, SMALL INTERFERING;
RNAI THERAPEUTICS;
|
|
EID: 85008330554
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1614154 Document Type: Review |
|
Times cited : (142)
|
|
References (4)
|
